Equities

Riken Vitamin Co Ltd

Riken Vitamin Co Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments23,38419,15517,302
Total Receivables, Net23,11420,11618,715
Total Inventory18,58117,73515,076
Prepaid expenses------
Other current assets, total1,4421,1201,697
Total current assets66,52158,12652,790
Property, plant & equipment, net23,38223,63725,428
Goodwill, net------
Intangibles, net976645698
Long term investments21,51917,88719,167
Note receivable - long term--01.00
Other long term assets949900824
Total assets118,776105,223102,660
LIABILITIES
Accounts payable9,9008,2577,696
Accrued expenses5,6184,8084,656
Notes payable/short-term debt4,8007001,068
Current portion long-term debt/capital leases7,1452,6242,623
Other current liabilities, total3,6542,5352,178
Total current liabilities31,11718,92418,221
Total long term debt5,31512,40414,993
Total debt17,26015,72818,684
Deferred income tax4,6261,5792,038
Minority interest302619
Other liabilities, total1,075945869
Total liabilities42,16333,87836,140
SHAREHOLDERS EQUITY
Common stock2,5372,5372,537
Additional paid-in capital2,4662,4663,072
Retained earnings (accumulated deficit)65,29058,72965,426
Treasury stock - common(7954)(1633)(13785)
Unrealized gain (loss)9,6256,4887,304
Other equity, total4,6492,7581,966
Total equity76,61371,34566,520
Total liabilities & shareholders' equity118,776105,223102,660
Total common shares outstanding303333
Treasury shares - common primary issue3.350.897.90
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.